Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer
NCT05422911Phase 2Recruiting
- Sponsor
- Sun Pharma
- Start
- Aug 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I), apalutamide, enzalutamide in prostate cancer (PCa), sponsored by Sun Pharma. Started Aug 2022; status: recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)apalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05422911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422911.